- Home
- MAIA vs NRXP Comparison
MAIA vs NRXP Comparison
Compare MAIA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- NRXP
- Stock Information
- Founded
- MAIA 2018
- NRXP 2015
- Country
- MAIA United States
- NRXP United States
- Employees
- MAIA N/A
- NRXP N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- NRXP Health Care
- Exchange
- MAIA Nasdaq
- NRXP Nasdaq
- Market Cap
- MAIA 56.3M
- NRXP 58.5M
- IPO Year
- MAIA 2022
- NRXP N/A
- Fundamental
- Price
- MAIA $1.59
- NRXP $2.84
- Analyst Decision
- MAIA
- NRXP Strong Buy
- Analyst Count
- MAIA 0
- NRXP 5
- Target Price
- MAIA N/A
- NRXP $31.40
- AVG Volume (30 Days)
- MAIA 375.5K
- NRXP 562.9K
- Earning Date
- MAIA 08-11-2025
- NRXP 08-18-2025
- Dividend Yield
- MAIA N/A
- NRXP N/A
- EPS Growth
- MAIA N/A
- NRXP N/A
- EPS
- MAIA N/A
- NRXP N/A
- Revenue
- MAIA N/A
- NRXP N/A
- Revenue This Year
- MAIA N/A
- NRXP N/A
- Revenue Next Year
- MAIA N/A
- NRXP $231.16
- P/E Ratio
- MAIA N/A
- NRXP N/A
- Revenue Growth
- MAIA N/A
- NRXP N/A
- 52 Week Low
- MAIA $1.40
- NRXP $1.10
- 52 Week High
- MAIA $3.74
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- MAIA 50.99
- NRXP 56.21
- Support Level
- MAIA $1.46
- NRXP $2.26
- Resistance Level
- MAIA $1.65
- NRXP $2.81
- Average True Range (ATR)
- MAIA 0.09
- NRXP 0.23
- MACD
- MAIA 0.01
- NRXP 0.04
- Stochastic Oscillator
- MAIA 43.10
- NRXP 78.38
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.